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O-linked β-D-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) onto serine and threonine residues of
proteins is an important post-translational modification (PTM), which is involved in many crucial biological processes
including transcription, translation, proteasomal degradation, and signal transduction. Aberrant protein O-GlcNAcylation
is directly linked to the pathological progression of chronic diseases including diabetes, cancer, and neurodegenerative
disorders. Identification, site mapping, and quantification of O-GlcNAc proteins are a prerequisite to decipher their
functions. In this review, we mainly focus on technological developments regarding O-GlcNAc protein profiling.
Specifically, on one hand, we show how these techniques are being used for the comprehensive characterization of
certain targeted proteins in which biologists are most interested. On the other hand, we present several newly
developed approaches for O-GlcNAcomic profiling as well as how they provide us with a systems perspective to
crosstalk amongst different PTMs and complicated biological events. Promising technical trends are also highlighted to
evoke more efforts by diverse laboratories, which would further expand our understanding of the physiological and
pathological roles of protein O-GlcNAcylation in chronic diseases.
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Cellular proteins are often decorated by multiple post-
translational modifications (PTMs) including glycosylation,
phosphorylation, methylation, acetylation, and ubiquity-
lation (a detailed list of more than 400 different PTMs can
be seen at http://www.uniprot.org/docs/ptmlist), which
exert various biological functions in numerous processes.
Among all the PTMs, glycosylation, which generally in-
volves the covalent attachment of glycans to Ser/Thr/Asn
residues, is predicted to occur in 80-90% of all extracellular
and nucleocytoplasmic proteins and thus it is probably the
most abundant and structurally diverse [1,2]. The classical
glycosylation mainly occurs between Asn-linked (N-linked)
or Ser/Thr-linked (‘mucin-type’ O-linked) oligosaccharides
and cell surface and secreted proteins. However, O-linked
β-D-N-acetylglucosamine modification (O-GlcNAcylation)
is, 1) a monosaccharide modification onto hydroxyl groups
of Ser/Thr residues, which is not elongated to complex
sugar structures [3,4]; 2) almost exclusively on proteins
localized in the nucleus, cytoplasm, and mitochondria [5];
3) reversible and highly dynamic, which is controlled by* Correspondence: gwhart@jhmi.edu
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unless otherwise stated.two enzymes: O-GlcNAc transferase (OGT) (which cata-
lyzes the addition of O-GlcNAc to Ser/Thr residues [6-8])
and β-D-N-acetylglucosaminidase (O-GlcNAcase) (which
removes O-GlcNAc [9]); 4) interplayed with other PTMs
(e.g., reciprocal/competitive with phosphorylation [10-12]);
and 5) most common in metazoans.
Since its discovery in the early 1980s [3,4], O-GlcNAcy-
lation has been found to play key roles in many fundamen-
tal biological processes including epigenetic regulation,
transcription, translation, proteasomal degradation, sig-
nal transduction, stress response, and homeostasis, thus
O-GlcNAc regulates diverse physiological events like circa-
dian rhythm, memory formation, and learning [13-16]. Of
particular note, since the synthesis of UDP-GlcNAc, the
substrate donor for OGT, is tightly regulated by multiple
major metabolic pathways in cells (i.e., glucose metabo-
lism, amino acid metabolism, fatty acid metabolism and
nucleotide metabolism) via the hexosamine biosynthesis
pathway [17], O-GlcNAc is a sensitive nutrient sensor
which links cellular metabolism with versatile signaling
pathways. Therefore, it is not surprising that aberrant pro-
tein O-GlcNAcylation underlies the etiology and patho-
logical progression of a number of chronic metabolicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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neurodegenerative disorders [23,24].
Even though numerous techniques have been developed
during the last several decades to study O-GlcNAc (see
excellent reviews [25-30]), there is still a strong demand
for highly efficient tools, including methods for O-GlcNAc
site mapping and production of site-specific antibodies.
The development of facile and robust approaches for
the assignment of the O-GlcNAc sites on proteins, a
prerequisite for site-specific O-GlcNAc functional assays,
would greatly facilitate probing the important roles of pro-
tein O-GlcNAcylation in various cellular processes. In this
review, we mainly cover two aspects, 1) describe the clas-
sical and modern methods for the identification and site
mapping of targeted O-GlcNAc proteins from a historic
view, which would be helpful to biologists working on
certain protein(s) and 2) delineate some newly developed
enrichment and quantification techniques coupling with
mass spectrometry (MS) for large-scale O-GlcNAc pro-
filing from a proteomics view, which should offer a
systems perspective for the function of O-GlcNAcylation
on multiple proteins in physiology and diseases. More-
over, a discussion on future technology development for
O-GlcNAc protein profiling is provided.
Targeted O-GlcNAc protein profiling
As with other PTMs, O-GlcNAcylation of myriad pro-
teins confers significant functions including alterations
in protein stability and enzymatic activity, translocation
(e.g., from the cytosol to the nucleus), and regulation of
gene expression. Therefore, unambiguous identification
of the O-GlcNAcylation status of protein(s) is of primary
priority. Classical approaches, such as Western blotting
and autoradiography, are still commonly used to confirm
the existence of O-GlcNAc on targeted proteins.
Moreover, O-GlcNAcylation exerts diverse actions via a
site-specific manner. Akin to phosphorylation, O-GlcNA-
cylation can occur on multiple Ser/Thr residues of pro-
teins and O-GlcNAcylation on different sites often has
distinct functional consequences. Therefore, the compre-
hensive characterization of all modification sites on pro-
teins is a prerequisite to elucidate their roles. Biological
mass spectrometry, a relatively newly emerging technique,
has gained popularity for O-GlcNAc site assignment in
recent years.
Classical biochemical assay for the identification of protein
O-GlcNAcylation
UDP-[3H]-galactose labeling
Tritiated UDP-Galactose (i.e., UDP-[3H]-galactose)-based
‘hot labeling’ was used in the discovery of protein O-
GlcNAcylation nearly 30 years ago [3,4] and is still a gold
standard for determining protein O-GlcNAcylation status.In this approach, [3H]-galactose is added to the GlcNAc
moiety on target proteins by β1-4-galactosyltransferase
(GalT), allowing for detection by autoradiography. An-
other advantage is that by combining UDP-[3H]-galactose
labeling with β-elimination and subsequent analysis of the
released disaccharide product, the presence of a single
GlcNAc residue can be confirmed. Of note, 1) proteins
should be denatured for efficient incorporation of the
galactose residues; and 2) since tritium is not as sensitive
as other radiolabels, signals may take weeks to detect
by autoradiography. Moreover, treatment with peptide:
N-glycosidase F (PNGase F), a specific enzyme that re-
moves nearly all N-linked glycans which may contain ter-
minal GlcNAc residues, should be performed prior to
UDP-[3H]-galactose labeling. In addition, nuclear/cyto-
plasmic extraction might be helpful to reduce the po-
tential contamination of proteins from the endoplasmic
reticulum/Golgi apparatus, the intracellular machinery for
the synthesis of diverse types of glycans.
O-GlcNAc antibodies
The advent of a number of antibodies including CTD
110.6 [31], RL2 [32,33], and others [34-36] (see Table 1),
which recognize the GlcNAc moiety on proteins, greatly
expands the tools to probe O-GlcNAcylated proteins and
enables Western blotting a facile approach for detecting
protein O-GlcNAcylation. In comparison to the classical
UDP-[3H]-galactose labeling approach, blotting with
O-GlcNAc antibodies is a much more sensitive and con-
venient tool. Notably, each of these antibodies is raised to
a specific O-GlcNAc-dependent epitope and only recog-
nizes a subset of O-GlcNAc–modified proteins (although
CTD 110.6, which is relatively less dependent on the
protein structure, recognizes a wider range of O-GlcNA-
cylated proteins). Due to the partial complementarity to-
wards O-GlcNAc recognition between these antibodies,
their combined use often benefits the detection of protein
O-GlcNAcylation status. Thus, multiple immunoblotting
analysis with several antibodies is recommended to de-
termine whether the proteins of interest are modified by
O-GlcNAc.
It should be borne in mind that cross-reactivity between
O-GlcNAc and other sugars might occur when probing
with antibodies [37]. To avoid false positives, several proce-
dures can be included, 1) treatment with PNGase F, and 2)
O-GlcNAc competitive assay (i.e., preincubation of the
antibody with 0.1-1 M free GlcNAc before blotting to com-
pete the signal away), and 3) hexosaminidase treatment as
a negative control to exclude the ‘mucin-type’ O-linked gly-
cosylation. With the combination of upstream immuno-
precipitation (IP) from complex samples, antibody-based
immunoblotting remains the common practice for the
detection of protein O-GlcNAcylation. Moreover, by mea-
suring the intensity (e.g., with densitometry) of the target










Anti-body CTD110.6 IgM + + [31]
RL2 IgG + + [32,33]
HGAC39 IgG + [34]
HGAC49 IgM + [34]
HGAC85 IgG + + [34]
9D1.E4(10) IgG + + [35]
18B10.C7 (3) IgG + + [35]
1 F5.D6(14) IgG + + [35]
My95 IgG [36]
Lectin WGA/sWGA+ + + [38]
GSLII + + [39]
GlcNAc*: all terminal GlcNAc including α/β-GlcNAc.
sWGA+: succinated-wheat germ agglutinin. sWGA reduces its affinity for sialic acid and GlcNAc residues. As such, sWGA is typically used for immunoblotting while
WGA for purification.
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samples under different treatment conditions.
Although certain lectins (e.g., wheat germ agglutinin
(WGA) [38] and griffonia simplicifolia lectin II (GSLII)
[39]) also show some specificity to O-GlcNAc moieties,
they are more frequently used as an enrichment tool in-
stead, which will be discussed in more detail later in this
review.
Methods for O-GlcNAc site mapping
Even though the O-GlcNAc status of proteins can be con-
firmed by using antibodies and/or UDP-[3H]-galactose
labeling followed by autoradiography, it is indispensible to
know the exact modification sites if the detailed molecular
functions of site-specific O-GlcNAcylation are desired. To
this end, Edman sequencing and mass spectrometry (MS)
are the two main techniques that have been adopted.
Edman sequencing
Edman sequencing, which was initially developed for pep-
tide sequencing, has made great contributions to map
O-GlcNAc sites, especially in the early days of O-GlcNAc
research [40-43]. This approach is usually used in con-
junction with the UDP-[3H]-galactose labeling and high
performance liquid chromatography (HPLC). In general,
several steps are involved, 1) purified O-GlcNAc proteins
(e.g., via immunoprecipitation) are reacted with UDP-[3H]
galactose in the presence of GalT, 2) the resulting
[3H]-galactose-labeled proteins are digested (commonly
by proteases), with the digests separated by HPLC, and 3)
fractions with high liquid scintillation counting values
(containing radioactive-labeled O-GlcNAc peptides) are
subjected to manual or automated Edman sequencing.
The O-GlcNAcylated amino acids can be recovered andfurther characterized. However, there are several issues to
be addressed: 1) Since Edman degradation requires puri-
fied peptides for amino acid sequencing, the starting ma-
terial should be a purified protein or simple mixtures so
that there are no co-eluted peptides in the HPLC fractions
(pre-fractionation means like SDS-PAGE should be car-
ried out if the mixture is too complex for HPLC reso-
lution); and 2) Due to substantial sample loss (largely due
to multiple rounds of HPLC) and fairly low sensitivity, a
minimum of 20 pmole of starting material (where >20%
of the sample is O-GlcNAcylated) is generally required.
These caveats may cause problems for the O-GlcNAc site
mapping of low abundance endogenous proteins but it
should be amenable to recombinant proteins or synthetic
peptides when mass spectrometers are not available. This
approach would be very useful for the differentiation of
isobaric masses of O-GlcNAc modifications on peptides
(e.g., an O-GlcNAc moiety could be localized at one of the
several Ser/Thr residues in a peptide, while the peptide
mass is the same), which is often problematic for even
advanced mass spectrometers. In addition, the phenyl-
thiohydantoin derivatives of Ser/Thr-GalNAc and Ser/
Thr-GalNAc-Gal can be well separated with an Edman
sequencer [40].
Mass spectrometry (MS)
In contrast to Edman sequencing, MS is a powerful analy-
tical tool that enables obtaining accurate information of
proteins/peptides (e.g., molecular weight, amino acid se-
quence, and even sample quantity). Indeed, researchers
have fervently embraced almost every new instrumentation
advance in MS for O-GlcNAc research. Fast atom bom-
bardment mass spectrometry (FAB-MS), the first wide-
spread instrument suitable for ionizing peptides devised in
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labeled synthetic peptides in early 1990s [45]. Shortly
after FAB, the advent of electrospray ionization (ESI) [46]
and matrix-assisted laser desorption-ionization (MALDI)
[47], two ionization methods which are capable of directly
ionizing involatile and labile biomolecules, have revo-
lutionized the characterization of proteins/peptides. In
combination with new fragmentation techniques (e.g.,
collision induced dissociation (CID), high-energy collision
dissociation (HCD) [48], and electron transfer dissociation
(ETD) [49] and several mass analyzers (e.g., time of flight
(TOF), ion tap, and Orbitrap), the ESI/MALDI-based bio-
logical mass spectrometers provide tremendous impetus
to the study of biomedical sciences, including the profiling
of O-GlcNAcylated proteins. Moreover, the evolution of
mass spectrometry has helped analyzing O-GlcNAc in a
high throughput way. Undoubtedly, these advanced mass
spectrometry techniques remain to be the cornerstone
tools to date, due to the high sensitivity, selectivity, and
throughput.
Electrospray ionization-collision induced dissociation-tandem
mass spectrometry (ESI-CID-MS/MS)
Relative to matrix-assisted laser desorption ionization-time
of flight-tandem mass spectrometry (MALDI-TOF-MS/
MS), ESI-CID-MS/MS has gained enormous popularity
for its almost perfect demonstration of characterizing
many types of PTMs on proteins/peptides. However, re-
garding O-GlcNAc site mapping, limited success has been
achieved. For example, the electrospray ionization-col-
lision induced dissociation-quadrupole time-of-flight tan-
dem mass spectrometry (ESI-CID-Q-TOF-MS/MS) has
been used for direct identification of O-GlcNAc sites on
synthetic peptides [50] and from in-gel digests of over-
expressed serum response factor [51]. A major challenge
for direct detection by ESI-CID-MS/MS is that the glyco-
sidic bond between O-GlcNAc and its peptide sequence is
more susceptible to breakage than that of the peptide
backbone during CID, where relatively high collision
energy is often applied. Therefore, the O-GlcNAc group is
preferentially lost (producing an O-GlcNAc oxonium ion)
prior to peptide fragmentation and thus, the exact modifi-
cation sites can not be assigned. However, in some cases
when large amounts of material are available, a very low
percentage of fragment ions may still bear the O-GlcNAc
moiety and may be useful in identifying modification sites
(as exemplified in Figure 1) [52,53].
It is noteworthy that in comparison to conventional CID,
the newly developed HCD fragmentation can produce and
monitor the O-GlcNAc oxonium ion (+204.08) in a more
efficient way (Figure 1) [53]. Not only that, a series of frag-
ments of the O-GlcNAc oxonium ion (i.e., m/z 186.07, m/z
168.06, m/z 144.06, m/z 138.05, and m/z 126.05) can also
be generated at pronounced high intensity. One strikingbenefit of the O-GlcNAc oxonium ion and its fragments is
that they can serve as diagnostic ions for the presence of
O-GlcNAc on certain peptides, although it would be dif-
ficult to accurately designate sites by using CID or HCD
alone especially when there are more than one Ser/Thr
residues in the peptide sequence. Another feature is that
CID or HCD is adaptable to coupling with ETD (i.e., CID/
ETD-MS/MS or HCD/ETD-MS/MS), enabling more reli-
able identification and site mapping of O-GlcNAc peptides
via the alternating scanning mode or CID/HCD-triggered
ETD mode.
One way to take advantage of the currently prevalent
CID/HCD-MS/MS is to convert the labile glycosidic bond
to a CID/HCD-compatible bond which can withstand the
CID or HCD fragmentation. For example, alkaline-induced
β-elimination can convert the O-GlcNAcylated Ser or Thr
to 2-aminopropenoic acid and 2-amino-2-butenoic acid,
respectively [54], or further to sulfide derivatives in the
presence of reducing reagents (e.g., Dithiothreitol) [55].
Electrospray ionization-electron transfer dissociation-tandem
mass spectrometry (ESI-ETD-MS/MS)
A very recent breakthrough in MS is the invention of ETD
fragmentation technique [49]. Different from CID, ETD
induces cleavage of the backbone N-Cα bond, generating
c- and z-ions for peptide sequencing. More importantly,
ETD generally does not break the linkage between PTMs
and their modified residues, thus CID-labile PTMs can be
well preserved during ETD (Figure 1), providing specific
site information [56]. Therefore, the ESI-ETD-MS/MS
method has been increasingly adopted, largely facilitating
the direct site assignment of O-GlcNAcylated proteins (as
exemplified in [57-59]).
Of note, a combination of several fragmentation ap-
proaches is very helpful for in-depth characterization since
ETD tends to perform better than CID or HCD on higher
charge states (Z>2 positive charges) but yields a lower
number of total identifications due to its relatively slower
scan rate and lower fragmentation efficiency [60]. Indeed,
both CID/ETD-MS/MS [35,37,57,59] and HCD/ETD-MS/
MS [53] have increased the confidence of O-GlcNAcylated
peptide identification and site localization. In addition,
pulsed Q dissociation (PQD) has also been coupled with
ETD for a two-stage tandem MS approach for O-GlcNAc
peptide analysis, facilitating the detection of such peptides
by PQD at low collision energy and the identification and
site localization by ETD [61]. By integrating with OScore
[61], a scoring scheme which can discriminate O-GlcNAc
peptide spectra from those of naked peptides with >99%
specificity, O-GlcNAc peptides in the low fmole range
were detected and a 10-fold higher sensitivity than a single
data-dependent ETD-MS/MS experiment was achieved.
Although site-specific detection for O-GlcNAc pep-
tides with ETD has gained great success, its utility for
Figure 1 Respective spectra from CID (A), ETD (B), HCD (C), and zoomed in HCD (D) of standard O-GlcNAc modified peptide CKII
(PGGSTPVsSANMM, where ‘s’ represents the O-GlcNAc modified Ser). Note: “-HexNAc” or “-H2O” indicates the loss of HexNAc or H2O. Low m/z
range HCD displays a distinctive pattern of HexNAc fragments (D). (Adapted from [53], with the permission from American Chemical Society)
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(s) (i.e., the ‘top-down’ approach) is still to be explored.
Since ETD is also regarded to be advantageous for the
fragmentation of longer peptides or even entire proteins
[56], its application to O-GlcNAc analysis should be fea-
sible at least for small individual proteins, which would
provide another unique avenue for O-GlcNAc profiling.
Special considerations for O-GlcNAc sample preparation
To fulfill successful profiling of O-GlcNAc proteins of
interest, several aspects concerning O-GlcNAc sample
preparation should be considered beforehand, 1) starting
amount of proteins/peptides, 2) efficient digestion of pro-
teins, and 3) possible derivatization of O-GlcNAc peptides
(especially for ETD detection).
Immunoprecipitation (IP) is commonly used to purify
proteins of interest. However, for some biologically im-
portant proteins (e.g. transcription factors), which are
often of low abundance, IP may not be practical to obtain
enough material for the profiling of even lower abundantO-GlcNAcylated populations. In vitro OGT-labeling of re-
combinant proteins (or even synthetic peptides) followed
by MS should be informative on potential O-GlcNAc
modification sites. Another alternative approach involves
the co-expression of OGT in the presence of the target
protein (e.g., transcription factor Sp1 [62] and Tau [52]) in
E. Coli. In this approach, OGT can somehow O-GlcNAcy-
late its substrates. No matter which method is adopted,
further site-directed mutagenesis is necessary to verify the
actual O-GlcNAc modification sites of the endogenous
proteins in a given biological context.
Trypsin is often the preferred enzyme for protein diges-
tion. However, in terms of mapping O-GlcNAc sites on
certain proteins, adequate care should be taken. Although
no consensus sequence for O-GlcNAc modification has
been found so far, some O-GlcNAc proteins tend to have
functionally important sites in sequences with clustered
Ser/Thr residues and less or no arginine/lysine residues
(e.g., 374DSSTDLTQTSSSGTVTLP391 in serum response
factor [41], 887GFDT-SSSSSNSAASSSFK904 in Nucleoporin
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[59], and tandem repeats of the consensus peptide sequence
‘SPTSPS’ in the C-terminal domain of RNA Polymerase II
[42]). In such cases, digestion with trypsin is not always
the best choice. Instead, proteolysis with chemical clea-
vage (e.g., with cyanogen bromide) and digestion with
complimentary specificity enzymes (e.g., Asp-N, and
Glu-C) could be beneficial for improved detection of cer-
tain long peptides with few or no tryptic sites as well
as the assignment of their O-GlcNAc sites. Moreover,
considering the limited success in the detection of low-
charged peptides with ETD-MS/MS, derivatization to
certain residues (e.g., to the C-terminal carboxyl group
[63]) may also be performed to impart more positive
charges and thus improved detection and site mapping of
O-GlcNAc peptides.
O-GlcNAc site prediction
There are a number of bioinformatic software tools avail-
able for predicting modification sites for other PTMs [64].
However, only a few have been developed for O-GlcNAc
prediction, namely, YinOYang [65], OGlcNAcScan [66],
and O-GlcNAcPRED [67] (Table 2). With the analysis of
an independent test dataset, O-GlcNAcPRED seems to
have better performance than the other two predictors,
especially in terms of prediction sensitivity. Providing
the different computational models used, these tools
also show certain complementarity in the prediction of
O-GlcNAc sites. Undoubtedly, they may provide some
useful reference for the modification status and potential
O-GlcNAc sites as well as the experimental detection of
O-GlcNAc on proteins of interest by MS. Further matur-
ation of these tools (regarding the prediction accuracy and
sensitivity) and the development of new ones would
facilitate research on O-GlcNAcylation and proteomic
identification.
O-GlcNAc stoichiometry of proteins
Determination of O-GlcNAc stoichiometry of individual
proteins provides additional information for understanding
the function and regulation of protein O-GlcNAcylation.
However, the addition of O-GlcNAc (+203) does not
usually alter the apparent molecular weight of a protein
(unlike the classical N-linked and O-linked glycoproteins),
as judged by methods such as SDS-PAGE. Moreover, there
are no changes in the charge status, leading to anTable 2 Bioinformatic tools for O-GlcNAc site prediction
O-GlcNAc predictor Website
YinOYang http://www.cbs.dtu.dk/services/Y
dbOGAP (OGlcNAc Scan) http://cbsb.lombardi.georgetown
O-GlcNAcPRED (Not availableunchanged pI value for a protein (which is different from
phosphorylated proteins). Therefore, it is not feasible to
distinguish the O-GlcNAc modified population from the
naked one by SDS-PAGE itself. Recently, the development
of a mass-tagging strategy shows strength in quantifying
the O-GlcNAcylation level on specific proteins [68-71].
Basically, O-GlcNAcylated proteins are chemoenzyma-
tically labeled using an UDP-ketogalactose analog and then
reacted with an aminooxy-functionalized PEG mass tag
(e.g., 5kDa). By doing so, the O-GlcNAcylated species will
migrate differently than their native counterpart upon
SDS-PAGE, which can be easily visualized by immunoblot-
ting with antibodies against the protein of interest. The
relative O-GlcNAcylation level can thus be determined by
comparing the density of the modified species against that
of the total population. The striking feature of this ap-
proach is that the O-GlcNAcylation state (e.g., mono-,
di-, tri-) of proteins will be revealed if multiple bands as a
ladder can be observed. One potential caveat is that in-
complete labeling caused by either enzymatic or chemical
reaction may also result in multiple bands. Therefore, fur-
ther validation should be performed to confirm the multi-
O-GlcNAcylation status to obtain accurate amount of each
population for specific proteins.
Global O-GlcNAcomic profiling
MS-based proteomics, a powerful technology referring to
the analysis of the expression, localization, PTMs, and
interactions of proteins expressed by a genome at a spe-
cific time, has greatly changed our view about intricate
molecular networks [72-74]. By coupling high-resolution
separation (mainly 2-D gel electrophoresis and HPLC)
with unbiased isotopic labeling techniques, MS-based
proteomics is capable of providing comprehensive cha-
racterization of thousands of proteins. Concomitantly,
various enrichment methods toward specific PTMs have
emerged, largely advancing the qualitative and quantitative
analysis of PTM-proteomes including the O-GlcNAcome.
Furthermore, protein microarrays have also been used for
O-GlcNAcomic profiling.
Gel-based O-GlcNAcomics
Traditionally, 2-D gel electrophoresis separated spots
are visualized with dyes, fluorophores, radioactivity, or
antibody-based western blotting, enabling comparative
analysis of proteins. The combined use of 2-D gelAlgorithm models (Ref.)
inOYang/ Artificial neuronal network [65]
.edu/hulab/OGAP.html Support vector machine [66]
yet) Support vector machine [67]
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omic tool in the 1990s, has been applied to O-GlcNAc
analysis in some studies [75-78]. Although certain success
has been achieved, several issues which are closely related
to the 2-D gel separation technique itself should be ad-
dressed [79], including 1) low efficiency in the analysis of
hydrophobic or extremely acidic/basic proteins; 2) obscu-
rity of low abundance proteins; 3) low quantitative accu-
racy due to the limited dynamic range; and 4) general
unavailability of O-GlcNAc modification site information.
Gel-free O-GlcNAcomics
In comparison to 2-D gel electrophoresis, the gel-free
separation approach (especially multiple dimensional
HPLC for peptides) has catapulted MS-based proteomics
(including PTM-proteomics) to an unprecedented level.
As with other PTMs, O-GlcNAc proteins are generally
regarded to be substoichiometric (e.g., less abundant
than phosphorylation), although one study has shown
that hundreds of O-GlcNAc peptides could be automa-
tically identified from existing large-scale proteomic data
sets with the recently developed software Oscore [61,80].
Moreover, there is severe ion suppression for detecting
O-GlcNAc modified peptides in the presence of naked
peptides [26]. In addition, as aforementioned, no con-
sensus O-GlcNAc motif has been found yet. All the
hurdles make accurate O-GlcNAc site assignment a
challenging task. As with other PTMs, selective enrich-
ment for O-GlcNAc is indispensable, especially when
complex biological samples are to be analyzed.
According to the unique biochemical properties of
O-GlcNAc, an array of enrichment techniques has been
developed. With the aid of well-established quantifica-
tion methods, large-scale O-GlcNAcomic profiling has
begun to take off and contributed to a systems biological
understanding of cells under physiological or patho-
logical status.
Antibody based O-GlcNAc enrichment
High-affinity antibodies are generally the primary choice
to pull down proteins/peptides with certain PTM(s). Al-
though pan-specific antibodies (e.g., CTD 110.6, RL2)
work well for O-GlcNAc immunoblotting, they have ten-
tative applications for enriching O-GlcNAc proteins due
to their relatively low affinity. By using CTD 110.6-con-
jugated beads enrichment and MS, Wang et al. identi-
fied 45 potentially O-GlcNAcylated proteins from COS7
cells [81]. With the combination of SILAC (i.e., stable
isotope labeling with amino acids in cell culture), an ap-
parent increase in O-GlcNAcylation of >10 proteins
while a decreased O-GlcNAcylation of nearly 20 proteins
was observed upon inhibition of glycogen synthase
kinase-3 (GSK-3). With a similar approach, another
study reported the identification of dozens of O-GlcNAcproteins from COS7 cells [82]. Among them, a number
of proteins showed elevated levels of O-GlcNAcylation
in response to heat stress.
While the production of higher-affinity O-GlcNAc anti-
bodies seems extremely difficult, there has been a long-
standing interest to develop novel antibodies over the years.
The challenges of making O-GlcNAc antibodies mainly lie
in two aspects: 1) O-GlcNAc–modified epitopes are often
self-antigens that are tolerated by the immune system and
2) carbohydrate-protein interactions are relatively weak,
which complicates antibody maturation [26,35]. Conti-
nuous efforts, however, have been made to generate O-
GlcNAc antibodies that can be applied for immunocapture.
Recently, with three O-GlcNAc-specific monoclonal anti-
bodies [35] for the enrichment of O-GlcNAc proteins from
HEK293 cell lysates, 83 O-GlcNAc sites were identified
with HCD/ETD-MS/MS [53].
The combined usage of multiple antibodies and the
development of higher-affinity antibodies should further
improve the enrichment performance toward O-GlcNAc.
One shortcoming with antibody-based O-GlcNAc protein
enrichment is that proteins interacting with O-GlcNAcy-
lated ones would also be pulled down, leading to false
positive identification. Independent techniques (e.g., im-
munoblotting with CTD 110.6) should be used for con-
firmation. By combining this approach with an advanced
mass spectrometer (e.g., ETD-MS/MS), the accurate mo-
dification sites on O-GlcNAcylated proteins can be identi-
fied, which would be a definitive indicator for the protein
O-GlcNAcylation status.
Lectin based O-GlcNAc enrichment
Due to the binding interaction with the glycan structure
on glycoconjugates, lectins serve as an important tool in
glycoproteomics and glycomics [83]. However, only se-
veral lectins have been used for O-GlcNAc research so far.
Wheat germ agglutinin (WGA) is a lectin that recog-
nizes both terminal GlcNAc and sialic acid residues.
Although succinylated WGA (sWGA) increases the spe-
cificity to GlcNAc over sialic acid, its affinity toward
GlcNAc is compromised as well [29]. Therefore, sWGA
is mainly used for immunoblotting, although certain
success in the capture of O-GlcNAc proteins has been
shown in some cases. WGA, working as a dimer con-
taining four carbohydrate binding sites, has high affinity
interactions with complex glycans via multi-point bind-
ing [84]. Thus, it is not surprising that WGA shows a
much lower affinity for the monomeric O-GlcNAc. In-
deed, O-GlcNAc interaction with WGA is quite weak,
as demonstrated by the ~10 mM dissociation constant
for free GlcNAc to WGA [85]. In comparison to protein
enrichment, O-GlcNAc peptide enrichment has gained
much attention especially with the newly developed
WGA-based lectin weak affinity chromatography (LWAC)
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into an adequately long column (e.g., 3 meters), which is
then coupled downstream to a low flow rate isobaric
HPLC instrument. By doing so, compared to the unmo-
dified peptides, O-GlcNAc peptides are retarded by the
column and recovered in later eluting fractions. The ap-
plicability of this strategy was first demonstrated through
enrichment of 145 unique O-GlcNAc-modified peptides
from a postsynaptic density (PSD) preparation [86]. By
combining this enrichment approach with ETD-MS/MS,
Chalkley et al. identified 58 modification sites from mouse
PSD [87]. In a recent report, with the utilization of further
optimized LWAC enrichment and peptide separation
(i.e., offline fractionation via basic reversed phase high
performance liquid chromatography (bRPLC)), 1750 O-
GlcNAc sites were assigned to mouse brain synaptosomal
proteins [89], greatly benefiting the future investigation of
brain development and functions. In another study, with
the combination of LWAC and SILAC for the analysis of
the nuclear fraction from embryonic stem cells (ESCs),
the same group unambiguously found 142 O-GlcNAc
modification sites on 62 proteins, some of which are
essential to maintain the ESC-specific expression profile
[88]. Taken together, LWAC has shown reasonable affinity
towards clustered O-GlcNAc-bearing peptides as well as
singly and doubly O-GlcNAc-modified peptides. The suc-
cess of this technique has greatly expanded the O-GlcNAc
protein database. The more sophisticated application
of such columns (e.g., improved collection of desired
fractions to decrease loss of O-GlcNAc peptides) may pro-
mote a wider acceptance of this approach for the enrich-
ment of O-GlcNAc peptides.
Besides WGA, another lectin Ricinus communis ag-
glutinin I (RCA I) has been used for O-GlcNAc en-
richment as well. However, different from WGA toward
GlcNAc, RCA I can specifically recognize in vitro galac-
tosylated GlcNAc. In this approach, GlcNAc-bearing
peptides are incubated with UDP-galactose in the pre-
sence of GalT, with the resulting Galβ1-4-GlcNAc-pep-
tides captured by conjugated RCA I. Compared to WGA
for GlcNAc, RCA1 for Galβ1-4-GlcNAc (i.e., LacNAc)
shows a higher affinity (Ka=10μM). Although several
studies have used this approach for the enrichment of
O-GlcNAc peptides from individual proteins [91-93] and
improved binding specificity proposed, its feasibility for
large-scale application has yet to be evaluated.
Collectively, lectins (especially WGA) are useful tools
for the enrichment of O-GlcNAc peptides. To improve
the binding specificity and capacity, PNGase F treat-
ment is often required beforehand to remove N-linked
GlcNAc-terminating sugars on proteins/peptides. Other
lectins, which can improve the binding affinity to O-
GlcNAc, are still worthy to be exploited for increased
enrichment efficiency.Chemical derivatization-based O-GlcNAc enrichment
Compared with antibody- and lectin-based O-GlcNAc
enrichment, chemical derivatization is a large category
of indirect enrichment, which is often comprised of
three steps: derivatization, capture, and release. Specifi-
cally, the O-GlcNAc group is derivatized to add a handle
(e.g., biotin) that can be readily captured onto beads
(e.g., streptavidin-conjugated ones) and the released
tagged O-GlcNAc peptides will then be subjected to MS
detection. To date, several chemical-derivatization tech-
niques have been developed for O-GlcNAc enrichment.
Hydrazide chemistry
Hydrazide chemistry is a well-established method for N-
glycoproteomic profiling [94]. Recently, an appropriately
modified analog has been developed for O-GlcNAc en-
richment [95]. In this approach, several steps are involved:
1) a prolonged periodate oxidation is performed to con-
vert the O-GlcNAc group to its dialdehyde derivative, 2)
hydrazide resin is used to capture the oxidized O-GlcNAc
peptides, and 3) after proteolytic digestion, the resulting
modified peptides are released by hydroxylamine. With
this enrichment procedure followed by MS/MS, several
O-GlcNAc sites were identified from Drosophila melano-
gaster proteasome protein complex. To apply this tech-
nique for large-scale O-GlcNAc site mapping, two issues
may need to be further addressed, 1) to derivatize the less
active O-GlcNAc moiety (largely due to the trans config-
uration of the vicinal hydroxyls at positions C3 and C4),
harsher conditions in periodate oxidation should be used,
leading to undesired side reactions (e.g., oxidation of N-
terminal Ser/Thr) and thus high background, and 2) more
efficient and specific release of tagged O-GlcNAc peptides
would be beneficial for the detection and site assignment
of O-GlcNAc peptides.
β-elimination Michael addition (BEMA)
As aforementioned, O-GlcNAc can be removed from pro-
teins/peptides by mild β-elimination, with Ser and Thr
residues converted into their dehydrated equivalents (i.e.,
dehydroalanine and α-amino butyric acid, respectively)
[54]. Based on this chemistry, a refined approach, named
β-elimination Michael addition (BEMA), has been de-
veloped to mark the site of O-GlcNAc modification. In
BEMA, the α/β-unsaturated carbonyl is derivatized with
nucleophilic reagents (e.g., DTT or biotinylated pentyla-
mine/cystamine) and the resulting peptides can then be
enriched by thiol-capture resin or streptavidin-conjugated
beads. Since DTT is the preferred nucleophile, the β-
elimination Michael addition of DTT has been termed
BEMAD [55,96]. There are several striking features of this
method, 1) in comparison to the initial labile glycosidic
bonds in O-GlcNAc peptides, the final resulting sulfide
derivatives are stable enough during fragmentation and
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prevalent CID-MS/MS without relying on ETD tech-
nology and 2) quantitative O-GlcNAc site information can
be readily achieved by using isotopically labeled DTT (i.e.,
D6-DTT and D10-DTT). Of special note is that, although
phosphorylated peptides can also undergo BEMAD, faster
conversion to the BEMAD product under milder condi-
tions is achieved for O-GlcNAc peptides due to the more
easily eliminated O-glycosidic linkages [3,54,55,96-98],
with less undesired side reactions. Therefore, optimized
BEMAD conditions and appropriate sample pre-treatment
(e.g., with PNGase F) should be performed to avoid po-
tential false positive identifications. In addition, distinct
approaches (e.g., HCD-MS/MS or ETD-MS/MS, and im-
munoblotting) should be adopted for further validation.
By using the BEMAD approach, several O-GlcNAc sites
were determined from the key contractile proteins, such
as actin and myosin heavy chains, in skeletal muscle [99].
Recently, an adapted method involving β-elimination-
based derivatization with a biotin-cystamine tag followed
by streptavidin-conjugated beads has been developed
[100]. By differential isotopic labeling with either light
biotin-cystamine or deuterated heavy biotin-cystamine,
the specificity of the enrichment approach can be in-
creased. Several O-GlcNAc sites within the murine 20S
proteasome core complex were assigned.
The combined use of BEMAD and other techniques
(e.g., chemoenzymatic labeling), which could further
improve the enrichment specificity, is also favorable for
O-GlcNAc profiling.
Chemoenzymatic labeling
Chemoenzymatic labeling capitalizes on the merits of the
traditional GalT labeling and the advanced chemical de-
rivatization techniques (especially the ketone-aminoxy
process and bioorthogonal chemistry). Different from tra-
ditional GalT labeling, unnatural galactose analogues with
specific chemical handles, which can facilitate the subse-
quent capture procedure, are used in chemoenzymatic la-
beling. An engineered mutant of GalT (GalTY289L), which
has an enlarged binding pocket for the donor-substrate
[101], is the best choice to selectively derivatize O-GlcNAc
with galactose analogues. To date, two major kinds of such
analogues have been developed and used for chemo-
enzymatic labeling, i.e, ketone-bearing UDP-galactose and
azido-modified UDP-galactose (UDP-GalNAz).
In one approach, GalTY289L is used to transfer the keto-
galactose onto O-GlcNAc proteins and a biotin-aminoxy
reagent is then attached via the oxime formation (amino-
xylation). The biotin-tagged derivatives are visualized by
streptavidin blotting [102] or subjected to streptavidin-
conjugated beads enrichment followed by fluorescence
[103] or MS detection [104,105]. By incorporating this ap-
proach with isotopic dimethyl labeling and ETD-MS/MS,comparative quantification of O-GlcNAc levels from two
different brain populations was performed [105].
Another chemoenzymatic approach integrates UDP-
GalNAz-based GalTY289L labeling, copper (I)-catalyzed
azide-alkyne cycloaddition (click chemistry), and streptavi-
din-conjugated beads [106-110]. Since the biotin-strepta-
vidin interaction is extraordinarily stable (Kd~= 10-15 M
for the homo-tetramer streptavidin and 10-7-10-8 M for
monomeric streptavidin), one elegant way is to introduce
a UV-cleavable linker to afford improved release efficiency
of tagged peptides from streptavidin-conjugated beads
[107-109]. An additional advantage is that the released
peptides contain a basic aminomethyltriazoyl acetylgalac-
tosamine moiety, enabling efficient ETD fragmentation.
By using the combination of GalTY289L labeling, click
chemistry, UV-cleavage, and ETD-MS/MS, 141 O-GlcNAc
sites were identified from component proteins in HeLa
mitotic spindles and midbodies [109] and 458 O-GlcNAc
sites in 195 proteins from mouse cerebrocortical brain
tissue [108].
Moreover, the chemoenzymatic labeling approach can
be readily coupled with BEMAD and CID-MS/MS for
O-GlcNAc site mapping [111-114]. In one study, 35
O-GlcNAc sites corresponding to 25 O-GlcNAcylated
proteins were identified from erythrocytes [114]. In
addition, with the further integration of isobaric tag for
relative and absolute quantitation technique (iTRAQ),
the relative occupancy ratio between normal and dia-
betic erythrocytes was determined, revealing different
O-GlcNAcylation at individual sites on proteins under
distinct cellular conditions.
Metabolic labeling
In comparison to the enrichment methods mentioned
above, which are performed in vitro, metabolic labeling
offers an in vivo way to place a chemical handle onto
O-GlcNAc proteins. This approach is based on the uti-
lization of N-azidoacetylglucosamine (GlcNAz), an analog
to GlcNAc. Studies have shown that GlcNAz can be tole-
rated by enzymes in the GlcNAc salvage pathway genera-
ting UDP-GlcNAz, which can finally be accepted by OGT
and transferred to substrate proteins in living cells [115].
Therefore, by feeding cells with an appropriate amount of
peracetylated GlcNAz, proteins initially modified by O-
GlcNAc will be substituted with GlcNAz. Peracetylation
allows the compounds to enter the cells and endogenous
deacetylases rapidly remove the acetyl groups. GalNAz
may also be used for labeling O-GlcNAc modified pro-
teins, because it is readily epimerized to GlcNAz [116].
The GlcNAz-tagged proteins can be chemoselectively
conjugated with a biotinylated phosphine reagent or a bio-
tinylated alkyne reagent via Staudinger ligation [115,116]
or click chemistry [117-120], respectively. After strepta-
vidin-conjugated beads enrichment, tagged proteins are
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with this method, 185 O-GlcNAc sites were assigned to 80
proteins in HEK293 cells [120].
In other studies, the alkynyl-modified GlcNAc analog
(GlcNAlk) has been exploited as a chemical reporter
of O-GlcNAc modification in living cells [119,121]. In
combination with click chemistry (with an azide-biotin
reagent), streptavidin-conjugated beads enrichment, pro-
teolytic digestion and MS, 374 putative O-GlcNAc pro-
teins were identified [121]. One feature of GlcNAlk
labeling is that, while GlcNAz can be metabolically inter-
converted to GalNAz [116,122], GlcNAlk does not, sug-
gesting it may be a more specific metabolic reporter of
O-GlcNAc modification.
Collectively, metabolic labeling has shown some ad-
vantages for facile enrichment of O-GlcNAc proteins.
However, the major downside is that the cell’s enzymes
prefer the natural substrate over the non-canonical ones,
resulting in relatively low levels of tagging.
Quantification of O-GlcNAcylation
Global quantitative analysis of the levels of proteins and
their O-GlcNAc sites is key to a systematic understan-
ding of the molecular function of O-GlcNAc proteins in
various biological processes. The traditional quantitation
approach, which relies on high-resolution protein sepa-
ration by 2-D gels and mass spectrometry identification
of certain significantly altered spots, has been used for
probing changes of O-GlcNAc proteins from several cell
lines and tissues [75-78]. However, inherent drawbacks
of the 2-D gel separation technique hinder its appli-
cation for in-depth comparative analysis, as mentioned
above. In contrast, the integration of stable isotope label-
ing with gel-free separation, specific enrichment, and
mass spectrometry detection has been demonstrated to
be a very powerful tool to provide quantitative informa-
tion about O-GlcNAc changes between samples in con-
trol, diseases, and drug-perturbation conditions. There
are mainly two ways: in vivo metabolic labeling and
in vitro chemical reaction, to incorporate stable isotopes
into O-GlcNAc proteins/peptides for mass spectrometry
based quantification.
In vivo metabolic labeling-based O-GlcNAc quantification
As an in vivo approach, stable isotope labeling with amino
acids in cell culture (SILAC) allows proteins to be labeled
by growing cells in media containing isotopically labeled
amino acids (e.g., 13C/15 N-arginine, 13C/15 N-lysine, 13C/
2H-methionine). Due to the high quantification accuracy,
SILAC has become a versatile tool for multiple proteomic
applications [123-125]. Wang et al. evaluated O-GlcNAc
proteomic changes upon stimulation of cells by lithium, a
selective inhibitor to glycogen synthase kinase-3 (GSK-3)
which is extensively involved in many signaling pathways[81]. By combining SILAC, CTD 110.6-bound beads en-
richment, and LC-MS/MS, they identified 45 potentially
O-GlcNAcylated proteins, 10 of which showed increased
O-GlcNAcylation while 19 showed decreased O-GlcNAcy-
lation upon GSK-3 inhibition [81]. Their results indicate
a complex interplay between phosphorylation and O-
GlcNAcylation within signaling networks. With a similar
approach, Zachara et al. investigated the changes of O-
GlcNAcylated proteins of cells in response to heat shock
[82]. Amongst the proteins identified, some DNA-binding
proteins showed elevated levels of O-GlcNAcylation, sug-
gesting a role for O-GlcNAc in regulating DNA damage
signaling or repair. In another study, by using a com-
bination of SILAC, chemoenzymatic labeling-based en-
richment, and LC-MS/MS, altered phosphorylation of key
proteins in cellular midbodies was revealed upon the over-
expression of OGT [109], further illustrating the intricate
crosstalk between O-GlcNAcylation and phosphorylation
of proteins in the regulation of cell division.
Even though SILAC has been demonstrated to be a
powerful tool in quantitative proteomic studies for cul-
tured cells, it is still not very practical for analyzing bio-
logical samples that can not be grown in culture, such as
tissues or body fluids. The further development of SILAC
techniques (i.e., tissues and even whole animal-targeted
SILAC [126,127]) should further benefit related applica-
tions including quantitative O-GlcNAc profiling.
In vitro labeling-based O-GlcNAc quantification
As a non-biased approach, the in vitro labeling involves
incorporation of stable isotopic tags onto selective sites
on proteins/peptides via chemical reactions. Isotopic
labeling can be introduced at the N-/C-terminus, on
specific amino acid residues (e.g. cysteine [128]), or at
the C-terminus of peptides during trypsin-catalyzed-18O
labeling of proteins [129]. Amongst those techniques,
N-terminus-targeted labeling, especially the isobaric tags
for relative and absolute quantitation (iTRAQ) [130] and
isotope dimethyl labeling [131,132], has been adopted
for O-GlcNAc quantification. In one study, iTRAQ was
coupled with the chemoenzymatic labeling enrichment and
LC-MS/MS to investigate the extent of O-GlcNAcylation
on human erythrocyte proteins from diabetic and normal
individuals [114]. Twenty-five O-GlcNAcylated erythrocyte
proteins were identified with differential O-GlcNAcylation
level between diabetic and normal erythrocytes, suggesting
a potential regulatory role of O-GlcNAcylation on erythro-
cyte proteins in response to glycemic status. In another
study, isotope dimethyl labeling was used with chemoenzy-
matic labeling enrichment and LC-MS/MS for probing the
dynamics of O-GlcNAcylation in brain [105]. Differential
O-GlcNAcylation on several proteins involved in the
regulation of transcription and mRNA translocation
was revealed, suggesting important roles of protein O-
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neurons. As a quite different approach, BEMAD can
introduce isotopic labels (i.e., deuterated DTT) onto ori-
ginally O-GlcNAc modified Ser/Thr residues prior to the
thio-affinity enrichment [96], allowing the evaluation of
site-specific O-GlcNAc changes. Moreover, by normali-
zing the level of site specific O-GlcNAc peptides to that of
the corresponding proteins, relative site occupancy ratio
(ROR) between different biological contexts can be ob-
tained. By comparing iTRAQ based protein quantification
and isotopic DTT-mediated BEMAD-based O-GlcNAc
peptide quantification, the O-GlcNAc site occupancy on
erythrocyte proteins from diabetic and normal individuals
was determined [114]. Of note, certain proteins with sig-
nificant O-GlcNAc site occupancy changes may serve as a
sensitive diagnostic tool for the early detection of diabetes.
Label-free quantification approaches
There has been increasing interest in the development of
label-free mass-spectrometry quantification techniques,Figure 2 Scheme for the enrichment of O-GlcNAcylated proteins/pep
lectin enrichment (2), BEMAD (3), chemoenzymatic labeling (4) and metabolic
antibodies-conjugated beads, and the enriched ones are digested and identifi
into peptides, which are captured with lectin-conjugated resin (2), thio-capture
chemoenzymatic labeling (4), with the enriched peptides identified by tandem
GlcNAlk, and the GlcNAz- and GlcNAlk-containing proteins are subjected to cli
with the digests analyzed by tandem mass spectrometry. Note: The cocktail us
BEMAD) has also been applied in some cases.due to the potential limitations of the isotopic labeling-
based quantification approaches (e.g., increased comple-
xity of sample preparation, high cost of the reagents, and
incomplete labeling). One label-free approach is based on
the comparison of the peptide peak intensity or spectral
count [133], the applicability of which is still to be
explored for O-GlcNAc quantification though. Multiple
reaction monitoring (MRM) or selected reaction mo-
nitoring (SRM), a non-scanning technique primarily on
triple-quadrupole mass spectrometers, provides another
promising tool for the quantification of target proteins
[134]. Recently, MRM-MS has been applied to quantify a
standard O-GlcNAcylated peptide down to 3 fmol and
then monitor the increased O-GlcNAcylation of several
peptides of GSK-3β in human embryonic stem cells upon
the treatment with an O-GlcNAcase inhibitor [135].
Without doubt, by integrating sophisticated quantifi-
cation procedures with increasingly efficient enrichment
methods and advanced MS techniques, O-GlcNAcomic
profiling is foreseeable in the near future, which wouldtides. Most commonly used strategies with antibody enrichment (1),
labeling (5) are illustrated. In (1), proteins are captured onto antibody/
ed by tandem mass spectrometry. In (2), (3), and (4), proteins are digested
column after BEMAD (3), and streptavidin-conjugated beads after
mass spectrometry. In (5), cells are fed with GlcNAc analogs GlcNAz and
ck chemistry, streptavidin-conjugated beads enrichment and digestion,
age of several methods (e.g., chemo-enzymatic/metabolic labeling and
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protein O-GlcNAcylation in diverse biological contexts.
Protein microarray-based O-GlcNAcomics
Distinct from MS, protein microarray represents another
high-throughput method for the analysis of PTMs such as
phosphorylation and N-glycosylation [136]. Tarrant et al.
used a protein array to screen for protein substrates of
O-GlcNAcylated and/or phosphorylated CKII [43]. Their
results reveal that the substrate spectrum changes after
binding to its interacting partner Pin1 and that the
substrate selectivity of CKII is delicately modulated by
O-GlcNAcylation and phosphorylation. To identify pro-
tein kinases that are potentially O-GlcNAcylated, Dias and
coworkers used a functional human protein array con-
taining 152 kinases as a substrate for OGT in vitro.
Intriguingly, they identified 42 kinases that are O-GlcNA-
cylated in vitro (~39% of all the kinases analyzed) [137],
suggesting that a number of protein kinases may be regu-
lated by O-GlcNAcylation and this regulation may further
complicate the already intricate relationship between
O-GlcNAcylation and phosphorylation. Indeed, recent
studies have shown that a number of important kinases
(including CKII [43], CaMKIV [138], PKC [139], Akt
[140], IκB kinase [141], among others) are regulated by O-
GlcNAcylation. With the further optimization and im-
provement of related techniques, protein microarrays will
still be a valuable technology for O-GlcNAcomic studies.
Conclusions and perspectives
Over the first two decades since its discovery, O-GlcNAcy-
lation was determined to be on ~500 proteins [142]. With
the introduction of new enrichment techniques and ad-
vanced mass spectrometers, the number of O-GlcNAcy-
lated proteins has been increased to >4000 (a detailed list is
being compiled). More importantly, numerous O-GlcNAc
sites have also been mapped, which not only significantly
facilitate deciphering the crucial roles of O-GlcNAc on in-
dividual proteins in various biological processes, but also
provide us a much deeper insight on how this modification
closely interplays with many other PTMs (especially phos-
phorylation) in complex molecular networks.
However, we are still in the early stage of O-GlcNAc pro-
filing, compared to the rapidly maturing characterization
of other PTMs (e.g., phosphorylation, N-glycosylation,
lysine acetylation, and ubiquitination) for which a handful
of highly efficient and robust tools are available. Although
many enrichment methods have been developed for O-
GlcNAc proteins/peptides (Figure 2), they are still far from
being applicable routinely to the analysis of samples,
especially for complex ones when large-scale comparative
O-GlcNAcomic profiling is desired. Moreover, the newly
designed mass spectrometers (especially the ETD-equipped
ones) are not widely available to most labs, which hampersthe site-oriented O-GlcNAc functional assays. In addition,
there are limited software and algorithms specifically de-
signed for O-GlcNAc site prediction as well as mass spec-
trometry data mining.
Considering the extremely important roles O-GlcNAc
plays, the complete repertoire of O-GlcNAcylated proteins
as well as their specific sites must be defined. To this end,
several aspects about improving O-GlcNAc profiling are
anticipated. 1) Refinement of current enrichment tech-
niques and development of novel ones should still be a
topic of intense interest. 2) How to make full use of the
capacity and improve the performance of mass spectro-
meters for O-GlcNAc detection remains to be addressed.
The combination of different fragmentation modes (e.g.,
HCD plus ETD) would be a powerful tool for improved
O-GlcNAc identification and site mapping. Moreover, the
potential for ETD in applications, such as multiple reaction
monitoring (MRM) for O-GlcNAc peptides and top-down
characterization for O-GlcNAc proteins, should be ex-
plored. 3) Quantitative proteomic techniques should be
further adopted in more O-GlcNAc studies. 4) Designing
novel bioinformatic tools for O-GlcNAc research will be
another goal in the future. 5) The development of a large
number of site-specific antibodies, as are now available for
protein phosphorylation, will be critical to the rapid ad-
vancement of this field by biologists. Taken together, as
with other PTMs, technology integration will hasten the
maturation of diverse methods for O-GlcNAc profiling.
We are sure that the technology-driven O-GlcNAcomics
will boom soon, which would profoundly contribute to the
elucidation of crucial functions of protein O-GlcNAcyla-
tion in versatile physiological and pathological conditions
and to a systems perspective of molecular mechanisms in
biological networks.Abbreviations
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